1. Introduction
===============

As one of the leading causes of mortality, cancer constitutes a major health burden worldwide ([@b1-ijmm-43-02-0647]-[@b4-ijmm-43-02-0647]). Its incidence has maintained an upward trend in recent decades due to an increasing prevalence of established risk factors, such as air pollution, diabetes, being overweight, physical inactivity, smoking, lifestyle changes and notably, the aging of the population ([@b2-ijmm-43-02-0647],[@b3-ijmm-43-02-0647]). Although major advances have been made in cancer research, there is still much uncertainty, both among the public and among researchers, as regards certain fundamental questions. For example, while cancer is clearly a genetic disease, it remains unclear as to why only a minority of individuals with certain oncogenic mutations (e.g., KRAS mutations) develop cancers. In addition, while smoking is a well-known risk factor for the development of lung cancer, it is unclear as to why the majority of smokers are exempt from this malignancy. More importantly, while \>90% of cancer-related mortality is attributed to metastases, it remains unclear as to why specific organ failure is rarely observed at the time of a patient's death. In this review, we propose the integrative theory, in which both oncogenic mutations and tumor-host interaction determine the fate of the cancer and host ([Fig. 1](#f1-ijmm-43-02-0647){ref-type="fig"}). Moreover, cancer is clearly a genetic disease, while tumor biology is basically the nature of the host.

2. Tumor metabolism is reprogrammed for rapid growth
====================================================

Similar to normal cells, cancer cells require adenosine triphosphate (ATP) and nutrients to proliferate. However, they notably differ from normal cells due to their dependence on glycolysis even under aerobic conditions, which is known as the Warburg effect ([@b5-ijmm-43-02-0647]-[@b7-ijmm-43-02-0647]). This phenomenon has been well demonstrated by the wide use of 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) for tumor detection in clinical practice, which shows an increased glucose uptake in tumors by the glycolysis process ([@b7-ijmm-43-02-0647]). Compared with tricarboxylic acid (TCA) releasing 36 ATPs per cycle, glycolysis is rapid, but inefficient, producing only 2 ATPs each cycle ([@b8-ijmm-43-02-0647]).

The Warburg effect may be explained by the increased biosynthetic demand of cancer cells, as glycolysis can provide metabolic intermediates for cellular biosynthesis ([Fig. 2](#f2-ijmm-43-02-0647){ref-type="fig"}) ([@b9-ijmm-43-02-0647]-[@b11-ijmm-43-02-0647]). Human bodies are exposed to various types of chronic irritations, including air pollution, smoking, infection, a high-fat and high-protein diet, alcohol consumption and radiation. Based on the evolution theory, cells with the potential to rapidly self-renew (stem and progenitor cells) are susceptible to irritations and remodel to rapid growth ([@b12-ijmm-43-02-0647]). Long-term or strong irritations may cause genetic mutations in normal cells ([@b13-ijmm-43-02-0647]). These genetic mutations, alongside with inherited genetic alterations, can induce cancer with uncontrolled rapid growth, which is the leading feature of malignancy ([@b12-ijmm-43-02-0647],[@b14-ijmm-43-02-0647],[@b15-ijmm-43-02-0647]). Tumor cells can obtain anabolic substrates (e.g., 5-ribose phosphate) to support uncontrolled growth through aerobic glycolysis and the pentose phosphate pathway (PPP) ([@b16-ijmm-43-02-0647]). The major hallmarks of cancer cells universally center on maintaining uncontrolled rapid growth, including sustaining proliferative signaling, evading growth suppressors, enabling replicative immortality, inducing angiogenesis, genomic instability and mutations, and resisting cell death ([@b17-ijmm-43-02-0647]). Indeed, normal cells with the ability of rapid division and growth (e.g., embryonic cells) also harbor active glycolysis ([@b18-ijmm-43-02-0647]). Certain metabolites produced during embryo formation are increased in malignant tumors \[e.g., carcinoembryonic antigen (CEA) in colorectal cancer\] ([@b19-ijmm-43-02-0647]). Therefore, metabolism is reprogrammed for the rapid growth of cancer cells.

3. A host with an impaired metabolism generates metabolic catastrophe
=====================================================================

The host provides both nutrients and an exhaust system to support tumor growth via the tumor microenvironment. To cope with the reprogrammed metabolism in cancer cells, an intact metabolic system of the host is essential to maintain tumor growth. However, the metabolic capacity of the host can be impaired under certain conditions, such as aging, diabetes, obesity, a high-fat and high-protein diet, and physical inactivity. The reprogrammed metabolism in cancer cells and the impaired metabolic capacities in the host create a metabolic catastrophe, which inhibits easy cancer growth and accelerates its progression ([@b20-ijmm-43-02-0647]-[@b22-ijmm-43-02-0647]). This point has been supported by previous studies, which have demonstrated that cancer patients who are frail with metabolic capacities have a poorer prognosis than cancer patients with an intact metabolism ([@b23-ijmm-43-02-0647]-[@b25-ijmm-43-02-0647]), indicating that the combined effect of cancer and systematic disease (e.g., diabetes) is more detrimental than either factor alone (1+1\>2). Several conditions of impaired metabolic capacity are interpreted below.

Aging
-----

Aging has been considered the most potent carcinogen and it has aided the increased cancer incidence, as a growing number of the population nowadays live to an old age worldwide ([@b26-ijmm-43-02-0647],[@b27-ijmm-43-02-0647]). To a certain extent, cancer is largely an aging disease and it is similar to other age-related disorders, despite differential manifestations ([@b28-ijmm-43-02-0647]). In an experiment using animal models with TP53 mutation, a shorter latency of tumor development occurs when the gene is mutated in older animals ([@b29-ijmm-43-02-0647]). The accumulation of genetic mutations has been considered the major cause of cancer as a carcinogen, resulting in an assumption that the probability of cancer development is positively associated with age. However, this is contrary to clinical observations, in which the incidence of different types of cancer occurs at different ages (mesenchymal or hematopoietic cancers at a young age and epithelial carcinomas from ages between 40 to 80 years) ([@b30-ijmm-43-02-0647]). Moreover, cancer morbidity and mortality even decline in the oldest age group, including in centenarians ([@b31-ijmm-43-02-0647]). In fact, aging is featured by a progressive decline in the function of multiple tissues, with an increase in hyperplasia in renewable tissues ([@b28-ijmm-43-02-0647]). Normal cells with a strong renewal capacity are vulnerable to various types of stresses and have high probability of both stress-induced and spontaneous mutations ([@b32-ijmm-43-02-0647],[@b33-ijmm-43-02-0647]). Additionally, aging is usually accompanied by an increasing chronic inflammation, which can stimulate cancer progression ([@b34-ijmm-43-02-0647]). Importantly, the metabolic capacity of the host is undoubtedly impaired as aging, creating a harsh and infertile milieu, forces the tumor to invade and colonize ([@b30-ijmm-43-02-0647]). Therefore, the association between cancer and aging is mainly due to the combined effects of genetic accumulation, immunologic degeneration and more importantly, age-related degeneration in the metabolic systems ([@b13-ijmm-43-02-0647],[@b30-ijmm-43-02-0647]-[@b33-ijmm-43-02-0647]).

Diabetes
--------

The association between cancers and diabetes has been noted for almost 200 years ([@b35-ijmm-43-02-0647]). Diabetes is a risk factor for various types of cancer, such as breast, pancreatic and colorectal cancers ([@b23-ijmm-43-02-0647],[@b24-ijmm-43-02-0647],[@b36-ijmm-43-02-0647],[@b37-ijmm-43-02-0647]). Importantly, diabetes is associated with the poorer worse survival of cancer patients ([@b25-ijmm-43-02-0647],[@b38-ijmm-43-02-0647]-[@b41-ijmm-43-02-0647]). A potential mechanism is that the metabolic capacity of diabetic patients is remodeled to hyperinsulinemia, insulin resistance and insulin-like growth factor (IGF) signaling, causing an enhanced HBP activation and O-GlcNAc synthesis ([@b42-ijmm-43-02-0647]-[@b44-ijmm-43-02-0647]). The metabolism of cancer cells is characterized by aerobic glycolysis, leading to a strengthened HBP activation and O-GlcNAc synthesis ([@b8-ijmm-43-02-0647],[@b45-ijmm-43-02-0647]). For patients suffering from both cancer and diabetes, the HBP pathway is magnified to produce O-GlcNAc, which plays a critical role in the oncogenic process via post-translational modification ([@b45-ijmm-43-02-0647]). This could be demonstrated by the clinical observation that patients with both cancer and diabetes presents dismal prognosis (1+1\>2) ([@b25-ijmm-43-02-0647]). The association between diabetes and pancreatic cancer is an example of this proposition. It has been shown that only 14% of patients with pancreatic cancer have normal fasting glucose values ([@b46-ijmm-43-02-0647]) and the association is more evident in cases with worsening or new-onset diabetes ([@b47-ijmm-43-02-0647],[@b48-ijmm-43-02-0647]). O-GlcNAc is the precursor of carbohydrate antigen 19-9 (CA19-9), an important biomarker of pancreatic cancer ([@b49-ijmm-43-02-0647]). Patients with normal levels of CA19-9 have been shown to have a surprisingly improved survival than patients with CA19-9 overproduction ([@b50-ijmm-43-02-0647]). Meanwhile, serum CA19-9 levels are often elevated in diabetic patients and correlate with poor glycemic control ([@b51-ijmm-43-02-0647],[@b52-ijmm-43-02-0647]). For diabetic patients with pancreatic cancer, the synergistic effect of O-GlcNAc synthesis promotes CA19-9 overproduction and cancer progression.

Obesity
-------

Obesity has long been known as a risk factor of various types of cancer ([@b53-ijmm-43-02-0647]-[@b55-ijmm-43-02-0647]) and its prevalence has been rapidly increasing over the past two decades ([@b55-ijmm-43-02-0647]). Moreover, obesity is recognized as an adverse prognostic factor for cancer patients and it accounts for 14% of all cancer-related deaths in men and 20% in women in the US ([@b56-ijmm-43-02-0647]-[@b58-ijmm-43-02-0647]). Obese patients with cancer are often diagnosed at an advanced stage ([@b55-ijmm-43-02-0647]). The connection between obesity and cancer mainly relates to metabolic reprogramming caused by the prevalence of type II diabetes and insulin resistance, leading to insulin and IGF-1 overproduction ([@b55-ijmm-43-02-0647],[@b59-ijmm-43-02-0647]). Increased levels of circulating free fatty acids in obese individuals induce insulin resistance as a consequence of metabolic adaptation ([@b55-ijmm-43-02-0647]). In addition, chronic inflammation is common in obese individuals, which further promotes cancer evolvement ([@b59-ijmm-43-02-0647]). For example, in hepatocellular carcinoma, obesity enhances the production of the tumor-promoting cytokines, interleukin (IL)-6 and tumor necrosis factor (TNF), leading to liver inflammation and activation of the oncogenic transcription factor, signal transducer and activator of transcription 3 (STAT3) ([@b60-ijmm-43-02-0647]). Furthermore, autophagy is deregulated in obese individuals, and the dysfunction of autophagy in the context of apoptosis resistance may cause tumor cell necrosis and inflammation ([@b59-ijmm-43-02-0647]). In brief, obesity facilitates cancer evolvement by metabolic reprogramming, inflammatory reaction and autophagy dysfunction.

Diet
----

Contrary to normal cells, the metabolism of cancer cells is reprogrammed to meet growth needs, requiring augmented calories and certain nutrients ([@b61-ijmm-43-02-0647],[@b62-ijmm-43-02-0647]). Caloric restriction, the consumption of fewer calories without inducing malnutrition, decreases the incidence of spontaneous cancers and inhibits cancer growth, although the effects are not uniform ([@b61-ijmm-43-02-0647],[@b62-ijmm-43-02-0647]). It can be achieved by a 10 to 50% decrease in caloric intake ([@b63-ijmm-43-02-0647]). Certain signals including insulin, IGF-1, phosphoinositide 3-kinase (PI3K), phosphatase and tensin homolog (PTEN) and mammalian target of rapamycin (mTOR) are associated with the reaction of dietary restriction ([@b63-ijmm-43-02-0647]), which can affect the response of tumors cells to major treatments ([@b64-ijmm-43-02-0647],[@b65-ijmm-43-02-0647]). For example, tumor cells present different reactions to high-dose chemotherapy from normal cells under conditions of dietary restriction, which is potentially mediated by homolog Ras2val19 and IGF-1 ([@b64-ijmm-43-02-0647],[@b65-ijmm-43-02-0647]). Furthermore, certain amino acids, such as leucine ([@b66-ijmm-43-02-0647]), glutamine ([@b67-ijmm-43-02-0647],[@b68-ijmm-43-02-0647]), serine ([@b69-ijmm-43-02-0647]), asparagine ([@b70-ijmm-43-02-0647]) and glycine ([@b71-ijmm-43-02-0647]) play an important role in cancer progression by interacting with major oncogenic signals, including KRAS, c-Myc and TP53. Therefore, caloric restriction and the restraint of certain nutrients may be promising strategies for cancer management.

4. Metabolic imbalance induces cancer formation
===============================================

As mentioned above, the metabolism of tumor cells is rewired to support unrestricted growth with rapid energy supply and anabolic materials ([@b6-ijmm-43-02-0647]). Moreover, certain byproducts (lactate, non-essential amino acids, oncometabolites, etc.) are increased and thus tumors require detoxification mechanisms to maintain easy growth ([@b8-ijmm-43-02-0647]). During physiological activities, accumulated metabolites can be recycled or excreted through bodies. For example, lactate produced during sports can be reused by the lactic acid cycle through the gluconeogenesis pathway, or can be changed into pyruvate and then entered the TCA cycle ([@b72-ijmm-43-02-0647]). For solid cancers, the host not only provides 'fuel' for tumor growth, but also functions as the exhaust system via the tumor microenvironment. Angiogenesis, some tumor cells (reverse Warburg effect), and stromal cells in the tumor microenvironment are coupled with cancers to support tumor growth by providing nutrients, recycling oncometabolites and transporting metabolic wastes ([@b17-ijmm-43-02-0647],[@b73-ijmm-43-02-0647]-[@b76-ijmm-43-02-0647]). Whether a metabolic balance between the tumor and host can be reached not only depends on the amount of oncometabolites produced by tumor cells, but more importantly, on the metabolic capacity of the host ([Fig. 3A](#f3-ijmm-43-02-0647){ref-type="fig"}). Diabetes, obesity, aging, fatty liver, alcohol consumption, chronic site inflammation, physical inactivity and the intake of certain types of food can impair the metabolic capacity of the host, resulting in a metabolic imbalance between the tumor and host ([Fig. 3B](#f3-ijmm-43-02-0647){ref-type="fig"}). The metabolic imbalance causes a metabolic catastrophe, compelling tumor cells to live in a harsh condition, which stimulates tumor death and provokes tumor cells to invade and metastasize. This is similar to a problematic car mismatched an advanced motor with an out-of-date exhaust system. Therefore, the evolvement of precancerous lesions (relative metabolic balance) to malignancy (moderate metabolic imbalance) and finally to metastatic cancer (severe metabolic imbalance) is driven by the metabolic imbalance between the tumor and host. For highly aggressive malignancies, the period from metabolic balance to imbalance is transient, making in situ carcinoma rapidly evolve into invasive cancer.

5. Metabolic imbalance forces the tumor to invade and metastasize
=================================================================

Although tumor cells can recruit stromal cells and promote angiogenesis to support their growth, the metabolic imbalance between the tumor and host can cause the accumulation of metabolic wastes, creating a dismal environment with metabolic catastrophe unsuited for tumor growth. The metabolic catastrophe stimulates tumor cells to invade adjacent tissues and metastasize to distant organs to couple their metabolic needs ([@b77-ijmm-43-02-0647],[@b78-ijmm-43-02-0647]). For instance, pancreatic cancer usually resides in a harsh environment with metabolic catastrophe (diabetes and chronic inflammation) and local invasion to nearby tissues (normal pancreas, nerves, bile duct and vessels) is common and associated with a poor prognosis ([@b79-ijmm-43-02-0647]). Moreover, the accumulation of metabolic waste can promote the death of tumor cells by necrosis, but not by apoptosis or autophagy ([@b80-ijmm-43-02-0647]). The inflammatory environment induced by necrosis further facilitates tumor invasion and metastasis ([@b81-ijmm-43-02-0647],[@b82-ijmm-43-02-0647]). Therefore, tumor invasion and metastasis are provoked by the metabolic imbalance between the tumor and host.

Metastasis occurs at an advanced stage of cancer evolvement. In 1889, Dr Stephen Paget proposed the well-known 'seed and soil' theory for cancer metastasis. However, even the sweetest soil is tougher than the soil in which the primary tumor resides ([@b83-ijmm-43-02-0647]). Metastasis is an inefficient process through which only a minority of migrating tumor cells can form metastatic foci ([@b84-ijmm-43-02-0647],[@b85-ijmm-43-02-0647]). In the primary tumor, stromal cells, certain tumor cells (reverse Warburg effect) and angiogenesis are coupled to re-use and excrete metabolic wastes ([@b17-ijmm-43-02-0647]). Although metastatic niches are preconditioned for tumor colonization ([@b86-ijmm-43-02-0647],[@b87-ijmm-43-02-0647]), different organs harbor distinct metabolic patterns and metastatic cancer cells that colonize different organs engage in different metabolic preferences ([@b88-ijmm-43-02-0647]). As regards breast cancer cells with a multiple metastatic capability (liver and lung), liver metastatic breast cancer cells use glucose uptake and glycolysis, while lung metastatic breast cancer cells employ glutamine uptake and oxidative phosphorylation (OXPHOS) to metastasize ([@b89-ijmm-43-02-0647]). Metastatic targeting is thus to do more with metabolic needs than simply a hemodynamic issue. In addition, as metastatic tumors can recruit less stromal cells and vasculature than the primary tumor, or tumor cells with the reverse Warburg effect may be incapable of metastasis, metastatic cells reside in a tough foreign microenvironment, causing a more severe metabolic catastrophe in metastases than that in the primary tumor ([@b88-ijmm-43-02-0647],[@b90-ijmm-43-02-0647]).

6. Metabolic imbalance stimulates cachexia
==========================================

Cancer cachexia is defined as a multifactorial syndrome presenting an ongoing loss of skeletal muscle mass (with or without loss of adipose tissue) that can be partially, but not entirely reversed by conventional nutritional support and leads to progressive functional impairment ([@b91-ijmm-43-02-0647]). It is often considered a paraneoplastic syndrome which is characterized by weight loss and inflammation ([@b92-ijmm-43-02-0647]-[@b94-ijmm-43-02-0647]). It becomes evident at the final stage of cancer and predicts a poor survival ([@b94-ijmm-43-02-0647]). Cancer cachexia is induced by a negative energy balance caused by a decreased food intake and increased energy expenditure ([@b92-ijmm-43-02-0647]). When human bodies consume enough exogenous nutrients, tumors mainly consume exogenous nutrients to sustain their rapid growth. However, the intake of nutrients in cancer patients is often reduced due to symptoms, such as fever, anorexia, pain and chronic systemic inflammatory response ([@b95-ijmm-43-02-0647]). Moreover, the needs for nutrients are increased in cancers for their inefficient consumption of nutrients (Warburg effect) and a systemic inflammatory response by secreting pro-cachexia mediators, such as transforming growth factor β (TGFβ), prostaglandin E2 (PGE2), IL-6, IL-1, TNF and interferon γ (IFNγ) ([@b92-ijmm-43-02-0647]-[@b94-ijmm-43-02-0647]). The negative energy balance induces the degradation of skeletal muscle and fat mass, leading to a set of cachexia-related symptoms, including severe thinness, weakness, fatigue and anemia ([@b92-ijmm-43-02-0647]-[@b95-ijmm-43-02-0647]). Therefore, cachexia is a hint of a cancer-related metabolic disorder.

7. Metabolic imbalance provokes systemic non-specific inflammation via tumor necrosis
=====================================================================================

There are three fundamental types of mammalian cell death, that is apoptosis, autophagy-associated cell death and necrosis ([@b96-ijmm-43-02-0647]). Apoptosis, a type of programmed cell death and an activating process by the consumption of ATP, is featured by the shrinkage of the cell and its nucleus without an obvious inflammatory response ([@b97-ijmm-43-02-0647]). Resistance to apoptosis is an essential feature of cancer development and effective chemotherapy and radiation act mainly through the induction apoptosis ([@b98-ijmm-43-02-0647]). Autophagy-associated cell death, a genetically controlled process, allows a starving or a sublethal cell to survive by recycling energy and metabolites via lysosome digesting their own organelles, particles and macromolecules ([@b99-ijmm-43-02-0647]). It is critical for maintaining cellular homeostasis and plays a context-dependent role in cancer evolvement ([@b100-ijmm-43-02-0647]). Necrosis, usually viewed as a non-programmed form of cell death, is caused by the rapid depletion of ATP (hypoxia, ischemia, or tumor growth outpacing angiogenesis), external stresses (infection, toxins, mechanical force, heat, or cold), and when apoptosis and autophagy are unlikely to continue if death stimuli persist ([@b96-ijmm-43-02-0647],[@b97-ijmm-43-02-0647],[@b101-ijmm-43-02-0647],[@b102-ijmm-43-02-0647]). In the process of necrosis, the early rupture of surface membranes allows an influx of extracellular fluids and a spillage of intracellular contents, resulting in cell and organelle swelling ([@b96-ijmm-43-02-0647]). It is worth mentioning that some types of necrosis are programmed, which are known as necroptosis, including TNF-induced programmed necrosis controlled by receptor-interacting serine/threonine-protein kinase 1 (RIP1) and receptor-interacting serine/threonine-protein kinase 3 (RIP3) ([@b101-ijmm-43-02-0647]). Unlike apoptosis and autophagy-associated cell death, necrosis is usually accompanied by an inflammatory response ([@b96-ijmm-43-02-0647],[@b97-ijmm-43-02-0647],[@b101-ijmm-43-02-0647],[@b102-ijmm-43-02-0647]).

The accumulation of metabolic wastes together with the lack of ATP supply lead to a metabolic catastrophe for cancer cells and ultimately cause their death ([@b7-ijmm-43-02-0647]). For cancer cells residing in a mild-stress environment, apoptosis is the main form of death for tumors with sufficient ATP supply ([@b102-ijmm-43-02-0647]). Furthermore, cancer cells require the catabolic process of autophagy to sustain an alternate energy source in periods of metabolic deprivation to prevent necrosis when the apoptosis of tumor cells is dysfunctional ([@b80-ijmm-43-02-0647],[@b103-ijmm-43-02-0647]). However, when metabolic catastrophe continues, or when the degree of metabolic stress becomes severe, metabolic stress triggers necrosis, which then becomes the major form of cancer cell death ([@b80-ijmm-43-02-0647]). Tumor necrosis is thus induced by metabolic catastrophe.

Coagulative necrosis is a common pathological feature of solid tumors ([@b104-ijmm-43-02-0647]-[@b106-ijmm-43-02-0647]). The presence of tumor necrosis has been reported as a dismal prognostic predictor in solid tumors ([@b104-ijmm-43-02-0647]-[@b107-ijmm-43-02-0647]). Following necrosis, tumor DNA is released outside the cell and becomes damage-associated molecular-pattern (DAMPs) ([@b108-ijmm-43-02-0647]). DAMPs, such as high mobility group box 1 (HMGB1) protein, can enter the circulation and activate a non-infectious inflammatory response ([@b108-ijmm-43-02-0647]). Tumor necrosis can induce both innate and adaptive immunologic responses, which are a 'double-edged sword' for cancer progression ([@b109-ijmm-43-02-0647]). Unlike apoptosis, in which several of the highly immunogenic intracellular proteins are sequestered into the dead cell, or autophagy-related cell death, in which the highly immunogenic intracellular proteins are degraded, necroptosis is a strong trigger of the adaptive immunologic responses, providing a critical and specific defense mechanism against cancer. Moreover, the detrimental side of necrosis is non-specific systemic inflammation, which can ultimately favor tumor progression and promote the death of the host ([@b109-ijmm-43-02-0647]).

8. Systemic non-specific inflammation causes cancer-related mortality
=====================================================================

Mechanic destruction caused by the primary tumor and distant metastases is widely believed to be the cause of cancer-related mortality ([@b110-ijmm-43-02-0647]). Moreover, organ dysfunction caused by metastases is often deemed as the major reason ([@b110-ijmm-43-02-0647]-[@b112-ijmm-43-02-0647]). For example, hepatic dysfunction caused by hepatic metastases is generally deemed as the major reason of pancreatic cancer-related mortality ([@b79-ijmm-43-02-0647]). However, a study demonstrated that a large proportion (63%) of patients with pancreatic cancer did not die of widespread metastatic disease, and even 12% of patients died of local pancreatic cancer ([@b113-ijmm-43-02-0647]). Another study found that the fraction (20%) of cases with diffuse liver metastases was relatively small at the time of death and only a minor proportion (14%) of patients with pancreatic cancer died from hepatic failure as a direct result of liver metastases ([@b114-ijmm-43-02-0647]). In fact, for healthy human beings, 1/3 of the normal liver volume can sustain the need of regular physiological activities. It is rarely observed that metastases of pancreatic cancer spread over 2/3 of the liver volume ([@b114-ijmm-43-02-0647]). Briefly, organ dysfunction caused by metastases is not the major immediate reason of cancer-related mortality.

Cancer-associated inflammation is a pivotal component of tumor progression and a critical determinant of outcome in patients with cancer ([@b17-ijmm-43-02-0647],[@b110-ijmm-43-02-0647],[@b115-ijmm-43-02-0647]). In early 1863, Rudolf Virchow observed leucocytes in neoplastic tissues and made a connection between the sites of chronic inflammation and cancer. Recent data of the inflammatory reaction in the tumor microenvironment has supported Virchow's hypothesis ([@b17-ijmm-43-02-0647]). Inflammation is now included as a hallmark of cancer and reciprocal interactions between cancer and inflammation accelerate the neoplastic process ([@b17-ijmm-43-02-0647],[@b81-ijmm-43-02-0647],[@b116-ijmm-43-02-0647]). To a certain degree, tumors are considered as wounds that never heal ([@b116-ijmm-43-02-0647]). Moreover, the links between cancer and inflammation are fostering novel anti-inflammatory therapeutic approaches for cancer prevention and treatment ([@b81-ijmm-43-02-0647]). However, previous studies have mainly focused on local inflammation surrounding the tumor, and have payed less attention to systemic inflammation in the host.

Cancer-related systemic inflammation, including hematopoietic changes (leucocytes, interleukins, interferons, hematopoietic growth factors, acute phase proteins, etc.) and alterations in neuroendocrine metabolism (endocrine hormones), has a more severe impact on the body than site inflammation in the tumor microenvironment ([@b95-ijmm-43-02-0647]). In general, for early-stage cancers, local inflammation is prominent at the primary tumor site; as tumor progression and systemic inflammation become more evident, inflammation peaks at the end stage of the disease, and induces a cachexic status ([@b95-ijmm-43-02-0647]). In ancient Greece, Hippocrates proposed the humoral theory, namely that the body had four humors: Black bile, yellow bile, blood and phlegm. He believed that an excess of black bile in various body sites caused cancer. This theory was embraced by the medical teachings of the influential doctor Galen. In the 17th century, the Dutch physician and chemist, Francois de la Boe Sylvius, an earliest defender of the theory of circulation of the blood, proposed that cancer was the outcome of chemical processes. Although the theory is debatable, inflammatory gradients in the blood system may play a similar role in cancer as 'black bile' in the humoral theory. Nowadays, the impact of cancer-related systemic inflammation upon the body has been well-established ([@b115-ijmm-43-02-0647],[@b117-ijmm-43-02-0647],[@b118-ijmm-43-02-0647]). In a study on 506 patients with various types of cancer, the single major reason of death was infection (36%) and it was also a contributory variable in an additional 68% of the patients, while organ invasion by neoplastic cells, including hepatic failure was the reason of death in 10% and a contributory factor in 5% of the cases ([@b119-ijmm-43-02-0647]). The degree of systemic inflammation can be effectively measured by the neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP) concentration and the Glasgow Prognostic Score (GPS), and these markers can be used to refine the stratification of patients to therapy and predict prognosis ([@b115-ijmm-43-02-0647],[@b117-ijmm-43-02-0647],[@b118-ijmm-43-02-0647]). The computed tomography 'bull's-eye sign' of hepatic metastases suggests that tumor necrosis is more common in metastases than in the primary tumor, indicating that the systemic inflammation induced by metastases is more severe than that induced by the primary tumor. This could explain why \>90% of cancer-related mortality is attributable to metastases, while usually no obvious organ failure is found at the time of patient's death ([@b83-ijmm-43-02-0647],[@b88-ijmm-43-02-0647],[@b110-ijmm-43-02-0647],[@b111-ijmm-43-02-0647]). Therefore, systemic aseptic inflammation is the major immediate cause of cancer-related mortality. To a certain degree, the immune system is designed not only to protect, but also to terminate human beings.

9. Hexosamine biosynthetic pathway (HBP) pathway regulates metabolism and cancer evolvement
===========================================================================================

The HBP pathway, another branch of glycolysis apart from the PPP pathway, constitutes of approximately 1-3% of total glucose flux in normal cells ([@b120-ijmm-43-02-0647]). It plays a prominent role in sensing nutrients fluctuation and regulating cellular metabolism through O- and N-linked glycosylation of serine and threonine residues, the most abundant and structurally diverse post-translational modification ([@b121-ijmm-43-02-0647],[@b122-ijmm-43-02-0647]). UDP-GlcNAc, a sensing molecule of metabolism, is the end product of the HBP pathway and O-GlcNAc transferase (OGT) adds O-GlcNAc to target proteins, while O-GlcNAcase (OGA) removes the modification ([@b123-ijmm-43-02-0647],[@b124-ijmm-43-02-0647]). The HBP flux is governed by both nutrient availability and nutrient-processing enzymes ([@b125-ijmm-43-02-0647]). Glucose, glutamine and Acetyl-CoA are substrates of the HBP biosynthesis and can affect the entry of nutrients into the HBP pathway ([@b125-ijmm-43-02-0647]). The HBP flux has been involved in a wide range of chronic conditions, such as cancer, diabetes, neurodegenerative disease and aging ([@b36-ijmm-43-02-0647],[@b123-ijmm-43-02-0647]). In cancer cells, the HBP pathway is highly augmented, which can be clearly demonstrated by widely used carbohydrate related biomarkers \[CA19-9, CEA, carbohydrate antigen 125 (CA125), etc.\] ([@b121-ijmm-43-02-0647],[@b124-ijmm-43-02-0647]). Oncogenic signals, such as KRAS can increase the flux of the HBP pathway by upregulating key enzymes of HBP and increasing the levels of glucosamine-6-phosphate (GlcN-6P), the product of the committed step governing flux into HBP ([@b16-ijmm-43-02-0647]). The augmented HBP pathway has a profound effect on cancer at various pathophysiological steps of tumor invasion and metastasis, immune evasion and the inflammatory response ([@b121-ijmm-43-02-0647],[@b124-ijmm-43-02-0647],[@b126-ijmm-43-02-0647]). In addition, it also plays a fundamental role in the coordination of nutrient uptake and metabolism, partially by modulating glutamine uptake and interplaying with other nutrient sensor pathways, such as GH-IGF1, mTOR, SIRT1, PI3K-AKT and the energy sensor AMP-activated protein kinase (AMPK) ([@b21-ijmm-43-02-0647],[@b126-ijmm-43-02-0647]). Therefore, as branches of glycolysis, the PPP pathway sustains cancer growth, while the HBP pathway enables cancer cells to evolve. A diet rich in substrates of the HBP pathway may modulate the progression of cancer ([@b68-ijmm-43-02-0647]).

10. The integrative theory applied in specific conditions
=========================================================

For young patients with cancer, particularly sarcoma, metabolic imbalance exists as the host provides a powerful metabolic system for tumor growth. The metabolic capacity even outpaces the growth needs of tumors cells ([Fig. 3C](#f3-ijmm-43-02-0647){ref-type="fig"}). Rapidly proliferating mesenchymal cells in children are vulnerable to various types of stresses, leading to malignant alterations with genetic mutations. Stromal cells create a nutrient-rich microenvironment to support tumor rapid growth and thus young patients are usually diagnosed with large tumors ([@b75-ijmm-43-02-0647]). Moreover, necrosis is not the major form of tumor death and it mostly presents in tumors with a low oxygen and blood supply, thus suggesting that these tumors are rarely associated with immune cell infiltration and inflammatory reaction ([@b82-ijmm-43-02-0647]).

For hematological malignancies, although the tumor microenvironment differs from that of solid tumors and metabolic wastes are recycled and excreted in a unique pattern, the metabolic and immunological capacity of the host also affects cancer evolvement.

For age-related death, although individuals are dead without tumor and other organic diseases, a systematic non-specific inflammation is also the major immediate reason. The systematic non-specific inflammation is induced by a metabolic imbalance caused by self-renewal needs and an impaired metabolism.

11. Therapeutic potential
=========================

It is well-recognized that cancer is exclusively a systemic disease with local appearance. Thus, tumor biology is not the properties of tumors, but the properties of an ecosystem containing both tumor and host. Modern therapeutic strategies are mainly focused on tumors, but rarely on the host. Researchers often note that experimental results are rarely repeated in patients during clinical trials. Experiments can be performed to examine the therapeutic efficacy by inhibiting uncontrolled tumor growth. However, as *in vitro* experiments have no external metabolism and the metabolic system of animal models differs from that of human beings, it is hard to replicate experimental results in patients with cancer during clinical trials. Therefore, therapeutic strategies should be an integrative mode by inhibiting uncontrolled tumor growth and improving host metabolic capacity. The metabolic capacity of human body can be impaired in certain circumstances, such as aging, diabetes, obesity, a high-fat and high-protein diet and physical inactivity. Accordingly, the correction of systemic metabolic disorders should be always kept in mind (calorie control, low-fat diet, proper exercise, controlling blood glucose levels, lose weight, metformin, etc.) ([@b127-ijmm-43-02-0647]). Furthermore, as systemic aseptic inflammation is the major immediate cause of cancer-related mortality, anti-inflammatory agents (e.g., non-steroidal anti-inflammatory drugs) could be used to control cancer progression ([@b128-ijmm-43-02-0647]). Activating adaptive immunologic response is a potential anti-cancer strategy, which is widely used in clinical practice nowadays ([@b129-ijmm-43-02-0647]).

For the fight against cancer, improving the metabolic and immunologic capacity of host should be as important as inhibiting cancer uncontrolled growth. Traditional Chinese medicine places great importance on improving the function of the human body. It emphasizes that human beings should live in harmony with nature. For cancers, it stresses cancer is not a disease, but rather a type of imbalance in the human body; thus, by improving the metabolic and immunologic capacity of the host, which may provide important clues for modern cancer treatment.

12. Conclusion
==============

In this integrative mode, chronic irritations induce tumor with genetic changes and rapid proliferation. Tumor cells employ aerobic glycolysis to sustain uncontrolled rapid growth. The host provides both nutrients and the exhaust system to support tumor growth via the tumor microenvironment. Whether a metabolic balance between tumor and host can be reached depends not only on the amount of oncometabolites produced by tumor cells, but more importantly, on the metabolic capacity of the host. Under certain circumstances, such as aging, diabetes, obesity and a high-fat diet, the exhaust system is impaired, inducing a metabolic imbalance between the tumor and host. The metabolic imbalance causes a metabolic catastrophe, forcing tumor cells to undergo necrosis, and invade and metastasize. Tumor invasion and metastasis is thus a passive, but not an active process. Intact apoptosis or autophagy allow tumor cells to live with the host in a homeostasis. However, tumor necrosis, particularly in metastases, leads to a systemic non-specific inflammation, which is the major cause of cancer-related mortality. This could explain why the majority of cancer-related mortality is attributable to metastases even without obvious organ dysfunction. Moreover, chronic irritation (e.g., smoking) or genetic alterations (e.g., KRAS mutations) cannot induce cancer development in metabolically intact individuals. Cancer residing in a host with metabolic defects usually presents an aggressive feature. Therefore, cancer can somewhat be viewed as the most severe complication of metabolic disturbance. Therapeutic strategies should perhaps follow an integrative mode by inhibiting uncontrolled tumor growth and improving host metabolic capacity. Traditional Chinese medicine may provide important clues for modern cancer treatment by proposing that the host should live in 'harmony' with cancer; i.e, instead of fighting the cancer, rather restore the body's balance.

In brief, there are three basic elements of cancer development in the integrative theory: Genetic alterations (cancer), metabolic imbalance (host) and immunologic response (host) ([Fig. 4](#f4-ijmm-43-02-0647){ref-type="fig"}). This theory views cancer in an integrative manner and proposes that both genetic changes and tumor-host interaction in metabolism and immunology determine the destiny of cancer and host. Although cancer is fundamentally a genetic disease, tumor biology is basically the nature of host.
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![Cancer with a reprogrammed metabolism. The metabolism of cancer is reprogrammed to support its rapid growth, which strengthens the glycolysis, PPP, and HBP pathways but attenuates the TCA cycle and glucogenesis. PPP, pentose phosphate pathway; HBP, hexosamine biosynthetic pathway; TCA, tricarboxylic acid cycle; LDH, lactate dehydrogenase.](IJMM-43-02-0647-g01){#f2-ijmm-43-02-0647}

![Metabolic interaction between tumor and host. (A) There is a metabolic balance in benign tumors and some indolent cancers. (B) For most adult patients with cancer, metabolic imbalance exists as the human body cannot sustain the needs of the rapidly growing tumor, leading to tumor cells becoming invasive and metastatic. (C) For young patients with sarcoma, metabolic imbalance occurs as the human body provides sufficient fuel and a powerful exhaust system to support its rapid growth.](IJMM-43-02-0647-g02){#f3-ijmm-43-02-0647}

![Diagram of the integrative theory for cancer. Three basic elements for cancer development in the integrative theory: genetic alterations (cancer), metabolic imbalance (host), and immunologic response (host). Interactions exist between these three factors. The combinedeffect of these elements determines the destiny of both cancer and host.](IJMM-43-02-0647-g03){#f4-ijmm-43-02-0647}
